Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 12, Issue 1, 1996, Pages 6-18

  Cleland, Alexander ^a   Watson, Henry G ^b   Robertson, Pamela ^a   Ludlam, Christopher A ^b   Leigh Brown, Andrew J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Antiviral chemotherapy; AZT; HIV 1; Mutations; Nucleotide sequence; Phylogenetic analysis; Resistance

Indexed keywords

ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; DRUG RESISTANCE; GENOTYPE; HEMOPHILIA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030003001     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199605010-00002     Document Type: Article

References (31)

1. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
2. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-8.
3. Boucher CA, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992;165:105-10.
4. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992;89:1934-8.
5. Kellam P, Boucher CA, Tijnagel JM, Larder BA. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol 1994;75:341-51.
6. Zhang LQ, Simmonds P, Ludlam CA, Leigh Brown AJ. Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates. AIDS 1991 ;5:675-81.
7. Mohri H, Singh MK, Ching WT, Ho DD. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc Natl Acad Sci USA 1993;90:25-9.
8. Najera I, Holguin A, Quinones-Mateu ME, et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995;69:23-31.
9. Japour AJ, Chatis PA, Eigenrauch HA, Crumpacker CS. Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization. Proc Natl Acad Sci USA 1991;88:3092-6.
10. Sheehy N, Desselberger U. Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains. J Gen Virol 1993;74:223-8.
11. Loveday C, Kaye S, Tenant-Flowers M, Semple M, Weller IVD, Tedder RS. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 1995;345:820-4.
12. Kaye S, Loveday C, Tedder RS. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type 1-infected patients treated with zidovudine. J Med Virol 1992;37:241-6.
13. Loveday C, Tedder RS. Enzyme-linked immunosorbent assays for the measurement of human immunodeficiency virus type 1 reverse transcriptase antigen and antibodies. J Virol Methods 1993;41:181-92.
14. Masquelier B, Pellegrin I, Ruffault A, et al. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine. J Acquir Immune Defic Syndr 1995;8:330-4.
15. Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO, Leigh Brown AJ. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol 1990;64:864-72.
16. Leigh Brown AJ, Simmonds P. Sequence analysis of virus variability based on PCR. In: Karn J, ed. HIV: a practical approach. Volume I, Virology and Immunology. Oxford: Oxford University Press 1995 pp 161-88.
17. Myers G, Korber B, Wain-Hobson S, Jeang KT, Henderson LE, Pavlakis GN. Human retroviruses and AIDS 1994. Los Alamos, NM: Los Alamos National Laboratory, 1994.
18. Winship PR. An improved method for directly sequencing PCR amplified material using dimethyl sulphoxide. Nucleic Acids Res 1989;17:1266 pgs.
19. Felsenstein J. PHYLIP - phylogeny inference package (version 3.2). Cladistics 1989;5:164-6.
20. Piatak M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-54.
21. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
22. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
23. Simmonds P, Zhang LQ, McOmish F, Balfe P, Ludlam CA, Leigh Brown AJ. Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis. J Virol 1991;65:6266-76.
24. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
25. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62.
26. Li WH, Tanimura M, Sharp PM. Rates and dates of divergence between AIDS virus nucleotide sequences. Mol Biol Evol 1988;5:313-30.
27. Albert J, Wahlberg J, Lundeberg J, et al. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera. J Virol 1992;66:5627-30.
28. Wahlberg J, Fiore J, Angarano G, Uhlen M, Albert J. Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type 1 variants. J Infect Dis 1994;169:611-4.
29. Albert J, Wahlberg J, Leitner T, Escanilla D, Uhlen M. Analysis of a rape case by direct sequencing of the human immunodeficiency virus type l pol and gag genes. J Virol 1994;68:5918-24.
30. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993;365:671-3.
31. Balzarini J, Karlsson A, Perez-Perez M-J, Camarasa M-J, Tarpley WG, De Clercq E. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single drug therapy. J Virol 1993;67:5353-9.